Program | Target | Indication | Discovery | Optimization | IND-enabling | Phase I | Phase II | Phase III | Partner |
---|---|---|---|---|---|---|---|---|---|
MRANK-001 | Small Molecule GLP-1RA | Obesity | Potential Best-in-Class | ||||||
Type 2 Diabetes | Potential Best-in-Class | ||||||||
MRANK-106 | DNA Damage Repair | Pancreatic cancer, etc | |||||||
MRANK-111 | CB1R | Obesity, etc. | |||||||
MRANK-101 | P53 | Oncology | |||||||
MRANK-103 (formerly 002) | MYC-high | Oncology | |||||||
MRANK-023 | Undisclosed | Undisclosed | |||||||
2 programs | Undisclosed | Undisclosed | Public Biotech | ||||||
8 programs | Undisclosed | Undisclosed | |||||||
EMRANK-016 | Allosteric Inhibitor | Oncology | PCC delivered | Public Biotech | |||||
EMRANK-189 | Undisclosed | Oncology | Lead delivered | Public Biotech |